Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results

Vanda Pharmaceuticals (VNDA) Reports Q2 EPS of $0.21, Revenues Beat; Offers FY19 HETLIOZ & Fanapt Combined Sales Outlook

July 31, 2019 5:31 PM EDT

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.21, versus $0.00 reported last year. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $54.15 million.

Reported net income applicable to common stockholders of $8.2 million, or $0.06 per diluted share, for the quarter ended June 30, 2019, as compared with $10.9 million, or $0.09 per diluted share, for the quarter ended June 30, 2018;Achieved Core Funds From Operations ("Core FFO") of $0.43 per diluted share for the quarter ended June 30, 2019, as compared with $0.41 per diluted share for the quarter ended June 30, 2018;Completed approximately 517,000 square feet of leasing during... More